Protein Therapeutics Market size to grow by USD 153.56 billion, the availability of favorable reimbursement policies to drive the market growth - Technavio

NEW YORK, April 27, 2023 /PRNewswire/ -- The protein therapeutics market size is forecast to increase by USD 153.56 billion from 2022 to 2027, at a CAGR of 9.14%, according to the recent market study by Technavio. The growth of the market will be driven by the increased demand for mAbs, development of novel therapies using innovative technologies, and availability of favorable reimbursement policies. For more detailed insights on the historic period (2017 to 2021) data and forecast market size (2023 to 2027) - Request a sample report 

Protein therapeutics market Vendor Analysis:

The global protein therapeutics market is subject to rapidly changing consumer demands and preferences. Changing consumer consumption patterns may affect vendor performance in the global protein therapeutics market. The market is fragmented because of several international and domestic vendors. Vendors compete based on several factors, such as quality, price, service, brand image, distribution, and marketing. 

Technavio has extensively analyzed 15 major vendors, including AbbVie Inc., Amgen Inc., AstraZeneca Plc, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., Creative Biolabs, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., Ipsen Pharma, Johnson and Johnson Services Inc., LGM Pharma LLC, Midas Pharma GmbH, Novartis AG, Novo Nordisk AS, Pfizer Inc., PV Pharma Healthcare Pvt. Ltd., and Sanofi SA

Vendor Offerings -

• AbbVie Inc. - The company offers protein therapeutics such as synaptic vesicle protein 2A.
• AstraZeneca Plc - The company offers protein therapeutics such as transthyretin protein.
• Biogen Inc. - The company offers protein therapeutics such as RITUXAN HYCELA.

Charts & data tables about market and segment sizes for a historic period (2017-2021) and forecast period (2023-2027) have been covered in this report. Download The Sample Report

Key Benefits for Industry Players & Stakeholders – 

• The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
• It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
• The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Grow your business significantly in the future - To get requisite details, ask for a custom report.

Market Segmentation:

This protein therapeutics market report extensively covers market segmentation by product (mABs, human insulin, erythropoietin, clotting factors, and others), application (metabolic disorders, immunologic disorders, hematological disorders, cancer, and genetic disorders), and geography (North America, Europe, Asia, and Rest of World (ROW)).

• The market share growth by the mABs segment will be significant for the overall market growth during the forecast period. The market is anticipated to expand as a result of rising cancer rates and the advantages of next-generation antibodies. Due to the alterations in lifestyle, such as smoking, drinking, and sedentary employment, the burden of cancer is increasing. As a result, alterations in lifestyle, such as smoking, drinking, and sedentary employment, the burden of cancer is increasing. Hence, such factors drive the segment growth, which in turn lead to the overall market growth during the forecast period.

Avail of the comprehensive analysis of the endoscopic closure devices market to evaluate and develop growth strategies. Download the Sample

Market Dynamics:

Key DRIVERS:

• The availability of favorable reimbursement policies notably drive the market growth for the protein therapeutics market.
• Protein therapeutics are expensive and cannot be afforded by everyone even though reimbursement of diagnostic tools and biological medicines is anticipated to drive the market during the forecast period.
• The status of drug reimbursement varies from region to region, with cost-effectiveness and other factors preventing coverage but the increasing demand for costly drugs is an important reason for these drugs to be included in reimbursement plans.
• Hence, such factors are expected to drive the growth of the global market during the forecast period.

Major Trends:

• The increase in chronic diseases is an emerging protein therapeutics market during the forecast period.
• The leading cause of disabilities and fatalities across the world is chronic diseases like Type 2 diabetes, cancer, chronic obstructive pulmonary disease, and CVDs.
• Unhealthy diets, lack of exercise, tobacco use, high blood pressure, high cholesterol, and obesity causes these diseases.
• Such factors result in the use of cutting-edge therapies like protein therapeutics.
• Hence, such factors fuel the market growth during the forecast period.

Key Challenges:

• The complicated regulatory framework is one of the major challenges impeding the market growth during the forecast period.
• Obtaining regulatory approval is frequently challenging, unpredictable, and arbitrary. Before being approved and put on the market, protein therapeutics must pass a variety of strict regulations. 
• The US is currently lagging behind other regulated markets, particularly the EU, in terms of the competition from biosimilar products.
• Inspite of the absence of new competitors, the US market for biosimilars continues to garner interest.
• Hence, such challenges hinder the market growth during the forecast period.

To get the key insights about inclusions and exclusions regarding market dynamics, buy the report 

What are the key data covered in this Protein Therapeutics Market report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the protein therapeutics market between 2023 and 2027
• Precise estimation of the size of the protein therapeutics market and its contribution to the market with a focus on the parent market
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the protein therapeutics market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information about vendors
• Comprehensive analysis of factors that will challenge the growth of protein therapeutics market vendors

Subscribe to our Basic Plan billed annually at USD 5000. 
Technavio's SUBSCRIPTION platform

Related Reports:

The alzheimer's disease therapeutics market is estimated to grow at a CAGR of 8.91% between 2022 and 2027. The size of the market is forecast to increase by USD 4,391.9 million. This report extensively covers market segmentation by drug class (cholinesterase inhibitors, n-methyl-d-aspartate receptor antagonist, and others), distribution channel (hospital pharmacy, retail pharmacy, and e-commerce pharmacy), and geography (North America, Europe, Asia, and Rest of World). The increasing awareness of alzheimer's disease is notably driving the market growth. 

The gastrointestinal stromal tumors therapeutics market size is expected to increase by USD 1.08 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.97%. Furthermore, this report extensively covers the gastrointestinal stromal tumors therapeutics market segmentation by route of administration (oral and parenteral) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The growing geriatric population is one of the key factors driving the gastrointestinal stromal tumors therapeutics (GIST) market growth.

Browse for Technavio's Health Care Market Reports 

Table of Contents:

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global protein therapeutics market 2017 - 2021 
• Exhibit 18: Historic Market Size – Data Table on Global protein therapeutics market 2017 - 2021 ($ billion)

• 4.2 Product Segment Analysis 2017 - 2021 
• Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ billion)

• 4.3 Application Segment Analysis 2017 - 2021 
• Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ billion)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

• 6.1 Market segments
• Exhibit 30: Chart on Product - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Product - Market share 2022-2027 (%)

• 6.2 Comparison by Product 
• Exhibit 32: Chart on Comparison by Product
• Exhibit 33: Data Table on Comparison by Product

• 6.3 mAbs - Market size and forecast 2022-2027 
• Exhibit 34: Chart on mAbs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 35: Data Table on mAbs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 36: Chart on mAbs - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on mAbs - Year-over-year growth 2022-2027 (%)

• 6.4 Human insulin - Market size and forecast 2022-2027 
• Exhibit 38: Chart on Human insulin - Market size and forecast 2022-2027 ($ billion)
• Exhibit 39: Data Table on Human insulin - Market size and forecast 2022-2027 ($ billion)
• Exhibit 40: Chart on Human insulin - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Human insulin - Year-over-year growth 2022-2027 (%)

• 6.5 Erythropoeitin - Market size and forecast 2022-2027 
• Exhibit 42: Chart on Erythropoeitin - Market size and forecast 2022-2027 ($ billion)
• Exhibit 43: Data Table on Erythropoeitin - Market size and forecast 2022-2027 ($ billion)
• Exhibit 44: Chart on Erythropoeitin - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on Erythropoeitin - Year-over-year growth 2022-2027 (%)

• 6.6 Clotting factors - Market size and forecast 2022-2027 
• Exhibit 46: Chart on Clotting factors - Market size and forecast 2022-2027 ($ billion)
• Exhibit 47: Data Table on Clotting factors - Market size and forecast 2022-2027 ($ billion)
• Exhibit 48: Chart on Clotting factors - Year-over-year growth 2022-2027 (%)
• Exhibit 49: Data Table on Clotting factors - Year-over-year growth 2022-2027 (%)

• 6.7 Others - Market size and forecast 2022-2027 
• Exhibit 50: Chart on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 51: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
• Exhibit 52: Chart on Others - Year-over-year growth 2022-2027 (%)
• Exhibit 53: Data Table on Others - Year-over-year growth 2022-2027 (%)

• 6.8 Market opportunity by Product 
• Exhibit 54: Market opportunity by Product ($ billion)
• Exhibit 55: Data Table on Market opportunity by Product ($ billion)

7 Market Segmentation by Application

• 7.1 Market segments
• Exhibit 56: Chart on Application - Market share 2022-2027 (%)
• Exhibit 57: Data Table on Application - Market share 2022-2027 (%)

• 7.2 Comparison by Application 
• Exhibit 58: Chart on Comparison by Application
• Exhibit 59: Data Table on Comparison by Application

• 7.3 Metabolic disorders - Market size and forecast 2022-2027 
• Exhibit 60: Chart on Metabolic disorders - Market size and forecast 2022-2027 ($ billion)
• Exhibit 61: Data Table on Metabolic disorders - Market size and forecast 2022-2027 ($ billion)
• Exhibit 62: Chart on Metabolic disorders - Year-over-year growth 2022-2027 (%)
• Exhibit 63: Data Table on Metabolic disorders - Year-over-year growth 2022-2027 (%)

• 7.4 Immunologic disorders - Market size and forecast 2022-2027 
• Exhibit 64: Chart on Immunologic disorders - Market size and forecast 2022-2027 ($ billion)
• Exhibit 65: Data Table on Immunologic disorders - Market size and forecast 2022-2027 ($ billion)
• Exhibit 66: Chart on Immunologic disorders - Year-over-year growth 2022-2027 (%)
• Exhibit 67: Data Table on Immunologic disorders - Year-over-year growth 2022-2027 (%)

• 7.5 Hematological disorders - Market size and forecast 2022-2027 
• Exhibit 68: Chart on Hematological disorders - Market size and forecast 2022-2027 ($ billion)
• Exhibit 69: Data Table on Hematological disorders - Market size and forecast 2022-2027 ($ billion)
• Exhibit 70: Chart on Hematological disorders - Year-over-year growth 2022-2027 (%)
• Exhibit 71: Data Table on Hematological disorders - Year-over-year growth 2022-2027 (%)

• 7.6 Cancer - Market size and forecast 2022-2027 
• Exhibit 72: Chart on Cancer - Market size and forecast 2022-2027 ($ billion)
• Exhibit 73: Data Table on Cancer - Market size and forecast 2022-2027 ($ billion)
• Exhibit 74: Chart on Cancer - Year-over-year growth 2022-2027 (%)
• Exhibit 75: Data Table on Cancer - Year-over-year growth 2022-2027 (%)

• 7.7 Genetic disorders - Market size and forecast 2022-2027 
• Exhibit 76: Chart on Genetic disorders - Market size and forecast 2022-2027 ($ billion)
• Exhibit 77: Data Table on Genetic disorders - Market size and forecast 2022-2027 ($ billion)
• Exhibit 78: Chart on Genetic disorders - Year-over-year growth 2022-2027 (%)
• Exhibit 79: Data Table on Genetic disorders - Year-over-year growth 2022-2027 (%)

• 7.8 Market opportunity by Application 
• Exhibit 80: Market opportunity by Application ($ billion)
• Exhibit 81: Data Table on Market opportunity by Application ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 82: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 83: Chart on Market share by geography 2022-2027 (%)
• Exhibit 84: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 85: Chart on Geographic comparison
• Exhibit 86: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027 
• Exhibit 87: Chart on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 88: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 89: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 90: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027 
• Exhibit 91: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 92: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 93: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 94: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027 
• Exhibit 95: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 96: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 97: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 98: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 
• Exhibit 99: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 100: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 101: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 102: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027 
• Exhibit 103: Chart on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 104: Data Table on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 105: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 106: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Canada - Market size and forecast 2022-2027 
• Exhibit 107: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibit 108: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibit 109: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 110: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.9 Germany - Market size and forecast 2022-2027 
• Exhibit 111: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 112: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 113: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 114: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.10 UK - Market size and forecast 2022-2027 
• Exhibit 115: Chart on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 116: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 117: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 118: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.11 China - Market size and forecast 2022-2027 
• Exhibit 119: Chart on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 120: Data Table on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 121: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 122: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 123: Market opportunity by geography ($ billion)
• Exhibit 124: Data Tables on Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 125: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape
• Exhibit 126: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption
• Exhibit 127: Overview on factors of disruption

• 11.4 Industry risks
• Exhibit 128: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 129: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 130: Matrix on vendor position and classification

• 12.3 AbbVie Inc.
• Exhibit 131: AbbVie Inc. - Overview
• Exhibit 132: AbbVie Inc. - Product / Service
• Exhibit 133: AbbVie Inc. - Key news
• Exhibit 134: AbbVie Inc. - Key offerings

• 12.4 Amgen Inc.
• Exhibit 135: Amgen Inc. - Overview
• Exhibit 136: Amgen Inc. - Product / Service
• Exhibit 137: Amgen Inc. - Key offerings

• 12.5 AstraZeneca Plc
• Exhibit 138: AstraZeneca Plc - Overview
• Exhibit 139: AstraZeneca Plc - Product / Service
• Exhibit 140: AstraZeneca Plc - Key news
• Exhibit 141: AstraZeneca Plc - Key offerings

• 12.6 Biogen Inc.
• Exhibit 142: Biogen Inc. - Overview
• Exhibit 143: Biogen Inc. - Product / Service
• Exhibit 144: Biogen Inc. - Key offerings

• 12.7 Bristol Myers Squibb Co. 
• Exhibit 145: Bristol Myers Squibb Co. - Overview
• Exhibit 146: Bristol Myers Squibb Co. - Product / Service
• Exhibit 147: Bristol Myers Squibb Co. - Key news
• Exhibit 148: Bristol Myers Squibb Co. - Key offerings

• 12.8 Creative Biolabs
• Exhibit 149: Creative Biolabs - Overview
• Exhibit 150: Creative Biolabs - Product / Service
• Exhibit 151: Creative Biolabs - Key offerings

• 12.9 Eli Lilly and Co.
• Exhibit 152: Eli Lilly and Co. - Overview
• Exhibit 153: Eli Lilly and Co. - Product / Service
• Exhibit 154: Eli Lilly and Co. - Key offerings

• 12.10 F. Hoffmann La Roche Ltd. 
• Exhibit 155: F. Hoffmann La Roche Ltd. - Overview
• Exhibit 156: F. Hoffmann La Roche Ltd. - Business segments
• Exhibit 157: F. Hoffmann La Roche Ltd. - Key news
• Exhibit 158: F. Hoffmann La Roche Ltd. - Key offerings
• Exhibit 159: F. Hoffmann La Roche Ltd. - Segment focus

• 12.11 Ipsen Pharma
• Exhibit 160: Ipsen Pharma - Overview
• Exhibit 161: Ipsen Pharma - Business segments
• Exhibit 162: Ipsen Pharma - Key offerings
• Exhibit 163: Ipsen Pharma - Segment focus

• 12.12 Johnson and Johnson Services Inc. 
• Exhibit 164: Johnson and Johnson Services Inc. - Overview
• Exhibit 165: Johnson and Johnson Services Inc. - Business segments
• Exhibit 166: Johnson and Johnson Services Inc. - Key news
• Exhibit 167: Johnson and Johnson Services Inc. - Key offerings
• Exhibit 168: Johnson and Johnson Services Inc. - Segment focus

• 12.13 LGM Pharma LLC
• Exhibit 169: LGM Pharma LLC - Overview
• Exhibit 170: LGM Pharma LLC - Product / Service
• Exhibit 171: LGM Pharma LLC - Key offerings

• 12.14 Novartis AG
• Exhibit 172: Novartis AG - Overview
• Exhibit 173: Novartis AG - Business segments
• Exhibit 174: Novartis AG - Key offerings
• Exhibit 175: Novartis AG - Segment focus

• 12.15 Novo Nordisk AS
• Exhibit 176: Novo Nordisk AS - Overview
• Exhibit 177: Novo Nordisk AS - Business segments
• Exhibit 178: Novo Nordisk AS - Key offerings
• Exhibit 179: Novo Nordisk AS - Segment focus

• 12.16 Pfizer Inc.
• Exhibit 180: Pfizer Inc. - Overview
• Exhibit 181: Pfizer Inc. - Product / Service
• Exhibit 182: Pfizer Inc. - Key news
• Exhibit 183: Pfizer Inc. - Key offerings

• 12.17 Sanofi SA
• Exhibit 184: Sanofi SA - Overview
• Exhibit 185: Sanofi SA - Business segments
• Exhibit 186: Sanofi SA - Key news
• Exhibit 187: Sanofi SA - Key offerings
• Exhibit 188: Sanofi SA - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 189: Inclusions checklist
• Exhibit 190: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 191: Currency conversion rates for US$

• 13.4 Research methodology
• Exhibit 192: Research methodology
• Exhibit 193: Validation techniques employed for market sizing
• Exhibit 194: Information sources

• 13.5 List of abbreviations 
• Exhibit 195: List of abbreviations

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio